The biomarker, S100 beta (S100B) in serum, has been shown to be a credible marker for assessing the severity of brain injury14,15 and predicting the outcomes of traumatic brain injury (TBI)16, stroke17, hypoxic-ischemic encephalopathy18, and postoperative delirium19. Here, S100B is linked to brain injury.